6505--Losartan Tablets

The Department of Veterans Affairs National Acquisition Center is seeking to establish a pharmaceutical contract for Losartan Potassium Tablets across multiple strengths and package configurations (25mg, 50mg, and 100mg in 30, 90, and 1,000 tablet bottles). The solicitation is designed to supply multiple federal agencies including VA, DoD, Indian Health Service, and Bureau of Prisons, with an aggregate contract covering a base year and four one-year option periods. Offerors must submit comprehensive pricing for all line items, including a mandatory 0.5% Cost Recovery Fee, and proposals are due by May 22, 2025 at 2:30 PM CT via electronic email submission. Critical requirements for vendors include providing unique NDC numbers, meeting FDA manufacturing standards, and ensuring specific packaging specifications such as safety caps and compatibility with automated dispensing units. Evaluation will likely focus on compliance with technical specifications, pricing, and overall ability to meet the comprehensive pharmaceutical supply needs across different federal agencies.

While the solicitation is technically unrestricted, it is effectively set aside for small businesses with a size standard of 1,300 employees. The contract anticipates annual requirements ranging from approximately 43,955 to 647,231 bottles per line item, representing a substantial pharmaceutical procurement opportunity. One award will be made in the aggregate for all nine line items, suggesting a comprehensive and consolidated approach to pharmaceutical procurement. The contract will serve multiple federal healthcare institutions, indicating a broad and strategically important supply chain initiative. Vendors must demonstrate capability to consistently manufacture and deliver Losartan Potassium Tablets that meet stringent federal healthcare standards, with performance expectations spanning multiple years and potentially significant volume requirements across different tablet strengths and packaging configurations.